Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation.
Xu H, Van der Jeught K, Zhou Z, Zhang L, Yu T, Sun Y, Li Y, Wan C, So KM, Liu D, Frieden M, Fang Y, Mosley AL, He X, Zhang X, Sandusky GE, Liu Y, Meroueh SO, Zhang C, Wijeratne AB, Huang C, Ji G, Lu X.
Xu H, et al. Among authors: liu y, liu d.
J Clin Invest. 2021 May 17;131(10):e146832. doi: 10.1172/JCI146832.
J Clin Invest. 2021.
PMID: 33830945
Free PMC article.